# Efficacy and Safety of CD5024 1% in Acne Vulgaris

> **NCT03034460** · PHASE2 · COMPLETED · sponsor: **Galderma R&D** · enrollment: 70 (actual)

## Conditions studied

- Acne

## Interventions

- **DRUG:** CD5024 1% cream
- **DRUG:** CD5024 cream placebo
- **DRUG:** CD0271/CD1579 gel
- **DRUG:** CD0271/CD1579 gel placebo

## Key facts

- **NCT ID:** NCT03034460
- **Lead sponsor:** Galderma R&D
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-25
- **Primary completion:** 2016-11-02
- **Final completion:** 2016-11-02
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2020-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03034460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03034460, "Efficacy and Safety of CD5024 1% in Acne Vulgaris". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03034460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*